Re: breast cancer fatigue

[Guest guest]

Heres the paper from Js article. These people were rather

successful in demonstrating an abnormality - with p = 0.0005, 83%

specificity, and 83% sensitivity. It would probably be worth looking

for the same biomarkers in CFS if it hasnt been done.

===========================================================

Clin Cancer Res. 2006 May 1;12(9):2759-66. Related Articles, Links

Inflammatory biomarkers for persistent fatigue in breast cancer

survivors.

Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR.

Cousins Center for Psychoneuroimmunology, University of California

at Los Angeles Semel Institute for Neuroscience and Human Behavior,

Los Angeles, California 90095-7076, USA.

PURPOSE: This study seeks to define immunologic and inflammatory

variables associated with persistent post-treatment fatigue in

breast cancer survivors. EXPERIMENTAL DESIGN: Leukocyte subsets,

plasma inflammatory markers, and ex vivo proinflammatory cytokine

production were assessed in 50 fatigued and nonfatigued breast

cancer survivors recruited > or = 2 years after successful primary

therapy. Multivariate statistical analyses were used to define a

composite immunologic biomarker of fatigue risk. RESULTS: Fatigued

breast cancer survivors were distinguished from nonfatigued

survivors by increased ex vivo monocyte production of interleukin

(IL)-6 and tumor necrosis factor-alpha following lipopolysaccharide

stimulation, elevated plasma IL-1ra and soluble IL-6 receptor (sIL-

6R/CD126), decreased monocyte cell-surface IL-6R, and decreased

frequencies of activated T lymphocytes and myeloid dendritic cells

in peripheral blood (all P < 0.05). An inverse correlation between

sIL-6R and cell-surface IL-6R was consistent with inflammation-

mediated shedding of IL-6R, and in vitro studies confirmed that

proinflammatory cytokines induced such shedding. Multivariate linear

discriminant function analysis identified two immunologic markers,

the ratio of sIL-6R to monocyte-associated IL-6R and decreased

circulating CD69+ T lymphocytes, as highly diagnostic of fatigue (P

= 0.0005), with cross-validation estimates indicating 87%

classification accuracy (sensitivity = 0.83; specificity = 0.83).

CONCLUSION: These results extend links between fatigue and

inflammatory markers to show a functional alteration in

proinflammatory cytokine response to lipopolysaccharide and define a

prognostic biomarker of behavioral fatigue.

PMID: 16675568 [PubMed - in process]